Fasted-State Simulated Intestinal Fluid "faSSIF-C", a Cholesterol Containing Intestinal Model Medium for in Vitro Drug Delivery Development

Journal of Pharmaceutical Sciences

Volumn 104, Issue 7, 2015, Pages 2213-2224

  Khoshakhlagh, Pooneh ^a   Johnson, Raphael ^a   Langguth, Peter ^a   Nawroth, Thomas ^a   Schmueser, Lars ^a,b   Hellmann, Nadja ^a   Decker, Heinz ^a   Szekely, Noemi Kinga ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

biorelevant media; Caco 2 cells; DLS; drug solubility; FaSSIF; in vitro models; light scattering; lipids; micelle; SANS

Indexed keywords

CARBAMAZEPINE; DANAZOL; FENOFIBRATE; GRISEOFULVIN; NANOMATERIAL; CHOLESTEROL;

ADENOCARCINOMA; ARTICLE; BIOCOMPATIBILITY; BIOLOGICAL MODEL; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FASTED STATE SIMULATED INTESTINAL FLUID WITH CHOLESTEROL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; LIGHT SCATTERING; MALE; NEUTRON SCATTERING; NORMAL HUMAN; PARTICLE SIZE; BODY FLUID; CACO 2 CELL LINE; DIET RESTRICTION; FEMALE; INTESTINE; INTESTINE ABSORPTION; METABOLISM; PHYSIOLOGY; PROCEDURES; SOLUBILITY; THEORETICAL MODEL;

BODY FLUIDS; CACO-2 CELLS; CARBAMAZEPINE; CHOLESTEROL; DANAZOL; DRUG DELIVERY SYSTEMS; FASTING; FEMALE; FENOFIBRATE; GRISEOFULVIN; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MALE; MODELS, THEORETICAL; PARTICLE SIZE; SOLUBILITY;

EID: 84934998890     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24470     Document Type: Article

References (57)

1. Amidon GL, Lennernäs H, Shah VP, Crison JR,. 1995. A theoretical basis for a biopharmaceutic drug classification-The correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm Res 12: 413-420.
2. Lennernäs H, Abrahamsson B,. 2005. The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J Pharm Pharmacol 57: 273-285.
3. Soderlind E, Karlsson E, Carlsson A, Kong R, Lenz A, Lindborg S, Sheng JJ,. 2010. Simulating fasted human intestinal fluids: Understanding the roles of lecithin and bile acids. Mol Pharm 7: 1498-1507.
4. Dressman JB, Amidon GL, Reppas C, Shah VP,. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15: 11-22.
5. Uppoor VR,. 2001. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 72: 127-132.
6. Moog F,. 1981. The lining of the small-intestine. Sci Am 245: 154-158.
7. Söderlind E, Dressman JB,. 2010. Physiology of oral drug absorption. In Oral drug absorption prediction and assessment;, Dressman JB, Reppas C, Eds. 2nd ed. New York, London: Informa Healthcare, pp 10-13.
8. Bates TR, Gibaldi M, Kanig JL,. 1966. Solubilizing properties of bile salt solutions II. Effect of inorganic electrolyte, lipids, and a mixed bile salt system on solubilization of glutethimide, griseofulvin, and hexestrol. J Pharm Sci 55: 901-906.
9. Mu HL, Holm R, Mullertz A,. 2013. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm 453: 215-224.
10. Fisher MM,. 1973. Sex differences in the bile acid composition of human bile: Studies in patients with and without gallstones. Can Med Assoc J 109: 190-193.
11. Hofmann AF,. 1984. The enterohepatic circulation of bile acids in man. In Handbook of physiology;, Schultz SG, Ed. Bethesda, Maryland: American Physiology Society, pp 567-596.
12. Admirand WH, Small DM,. 1968. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest 47: 1043-1052.
13. Persson EM, Nilsson RG, Hansson GI, Lofgren LJ, Liback F, Knutson L, Abrahamsson B, Lennernas H,. 2006. A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm Res 23: 742-751.
14. Kleberg K, Jacobsen F, Fatouros DG, Mullertz A,. 2010. Biorelevant media simulating fed state intestinal fluids: Colloid phase characterization and impact on solubilization capacity. J Pharm Sci 99: 3522-3532.
15. Somjen GJ, Gilat T,. 1985. Contribution of vesicular and micellar carriers to cholesterol transport in human bile. J Lipid Res 26: 699-704.
16. Venneman NG, Johannes van Erpecum K,. 2010. Pathogenesis of gallstones. Gastroenterol Clin N Am 39: 171-183.
17. Charman WN, Rogge MC, Boddy AW, Berger BM,. 1993. Effect of food and monoglyceride emulsion formulation on danazol bioavailability. J Clin Pharmacol 33: 381-386.
18. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB,. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 15: 698-705.
19. Klein S,. 2010. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J 12: 397-406.
20. Kleberg K, Jacobsen J, Müllertz A,. 2010. Characterising the behaviour of poorly water soluble drugs in the intestine: Application of biorelevant media for solubility, dissolution and transport studies. J Pharm Pharmacol 62: 1656-1668.
21. McNamara DP, Whitney KM, Goss SL,. 2003. Use of a physiologic bicarbonate buffer system for dissolution characterization of ionizable drugs. Pharm Res 20: 1641-1646.
22. Jantratid E, Janssen N, Reppas C, Dressman JB,. 2008. Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update. Pharm Res 25: 1663-1676.
23. Fotaki N, Vertzoni M,. 2010. Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations. Open Drug Deliv J 4: 2-13.
24. Kataoka M, Masaoka Y, Sakuma S, Yamashita S,. 2006. Effect of food intake on the oral absorption of poorly water-soluble drugs: In vitro assessment of drug dissolution and permeation assay system. J Pharm Sci 95: 2051-2061.
25. Buch P, Languth P, Kataoka M, Yamashita S,. 2009. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system. J Pharm Sci 98: 2001-2009.
26. Buch P, Holm P, Thomassen JQ, Scherer D, Kataoka M, Yamashita S, Langguth P,. 2011. IVIVR in oral absorption for fenofibrate immediate release tablets using dissolution and dissolution permeation methods. Pharmazie 66: 11-16.
27. MacGregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Pouton CW,. 1997. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Deliv Rev 25: 33-46.
28. Walter A, Vinson PK, Kaplun A, Talmon Y,. 1991. Intermediate structures in the cholate-phosphatidylcholine vesicle-micelle transition. Biophys J 60: 1315-1325.
29. Long MA, Kaler EW, Lee SP,. 1994. Structural characterization of the micelle-vesicle transition in lecithin-bile salt solutions. Biophys J 67: 1733-1742.
30. Nawroth T, Buch P, Buch K, Langguth P, Schweins R,. 2011. Liposome formation from bile salt-lipid micelles in the digestion and drug delivery model FaSSIF(mod) estimated by combined time-resolved neutron and dynamic light scattering. Mol Pharm 8: 2162-2172.
31. Nieh MP, Katsaras J, Qi X,. 2008. Controlled release mechanisms of spontaneously forming unilamellar vesicles. Biochim Biophys Acta 1778: 1467-1471.
32. Khoshakhlagh P, Johnson R, Nawroth T, Langguth P, Schmueser L, Hellmann N, Decker H, Szekely NK,. 2014. Nanoparticle structure development in the gastro-intestinal model fluid FaSSIFmod6.5 from several phospholipids at various water content relevant for oral drug administration. Eur J Lipid Sci Technol 116: 1155-1166.
33. Berne BJ, Pecora R,. 1976. Dynamic light scattering-With applications to chemistry, biology and physics. Mineola, New York: Dover Book Publications Inc.
34. Svergun DI, Koch MHJ, Timmins PA, May RP,. 2013. Small angle X-ray and neutron scattering from solutions of biological macromolecules. Oxford: Oxford University Press.
35. Radulescu A, Pipich V, Frielinghaus H, Appavau MS,. 2012. KWS-2, the high intensity/wide Q-range small-angle neutron diffractometer for soft-matter and biology at FRM II. J Phys: Conf Ser 351: 012026.
36. Guinier A,. 1939. La diffraction des rayons X aux tres petits angles; application a l'etude de phenomenes ultramicroscopiques. Ann Phys 12: 161-237.
37. Jahn MR, Nawroth T, Futterer S, Wolfrum U, Kolb U, Langguth P,. 2012. Iron oxide/hydroxide nanoparticles with negatively charged shells show increased uptake in Caco-2 cells. Mol Pharm 9: 1628-1637.
38. Buch K, Peters T, Nawroth T, Sanger M, Schmidberger H, Langguth P,. 2012. Determination of cell survival after irradiation via clonogenic assay versus multiple MTT assay-A comparative study. Radiat Oncol 7: 1-6.
39. Mosmann T,. 1983. Rapid Colorimetric assay for cellular growth and survival-Application to proliferation and cyto-toxicity assays. J Immunol Methods 65: 55-63.
40. Nakayama F, Vanderli W,. 1971. Bile composition-Sweden versus Japan-Its possible significance in difference in gallstone incidence. Am J Surg 122: 8-13.
41. Mukhopadhyay S, Maitra U,. 2004. Chemistry and biology of bile acids. Curr Sci India 87: 1666-1683.
42. Helenius A, McCaslin DR, Fries E, Tanford C,. 1979. Properties of detergents. Methods Enzymol 56: 734-749.
43. Fuchs A, Dressman J,. 2014. Composition and physiochemical properties of fasted-state human duodenal and jejunal fluid: A critical evaluation of the available data. J Pharm Sci 103: 3398-3411.
44. Müller K,. 1981. Structural dimorphism of bile salt/lecithin mixed micelles. A possible regulatory mechanism for cholesterol solubility in bile? X-ray structure analysis. Biochemistry 20: 404-414.
45. Kirby C, Clarke J, Gregoriadis G,. 1980. Effect of cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J 186: 591-598.
46. Raffy S, Teissi'e J,. 1999. Control of lipid membrane stability by cholesterol content. Biophys J 76: 2072-2080.
47. Vanderkoi G,. 1994. Computation of mixed phosphatidylcholine-cholesterol bilayer structures by energy minimization. Biophys J 66: 1457-1468.
48. Ohvo Rekilä H, Ramstedt B, Leppimäki P, Slotte JP,. 2002. Cholesterol interactions with phospholipids in membranes. Prog Lipid Res 41: 66-97.
49. Silvius JR,. 2003. Role of cholesterol in lipid raft formation: Lessons from lipid model systems. Biochim Biophys Acta 1610: 174-183.
50. Wennberg CL, van der Spoel D, Hub JS,. 2012. Large influence of cholesterol on solute partitioning into lipid membranes. J Am Chem Soc 134: 5351-5361.
51. Stahlberg D, Reihner E, Angelin B, Einarsson K,. 1991. Interruption of the enterohepatic circulation of bile-acids stimulates the esterification rate of cholesterol in human liver. J Lipid Res 32: 1409-1415.
52. Schulthess G, Compassi S, Boffelli D, Werder M, Weber FE, Hauser H,. 1996. A comparative study of sterol absorption in different small-intestinal brush border membrane models. J Lipid Res 37: 2405-2419.
53. Marschall HU, Einarsson C,. 2007. Gallstone disease. J Int Med 261: 529-542.
54. Zumbuel O, Weded HG,. 1981. Liposomes of controllable size in the range of 40 to 180 nm by defined dialysis of lipid/detergent mixed micelles. Biochim Biophys Acta 640: 252-262.
55. Marinetti GV,. 1990. Disorders of cholesterol metabolism. In Disorders of lipid metabolism. New York: Springer, pp 63-74.
56. Granero GE, Ramachandran C, Amidon GL,. 2005. Dissolution and solubility behaviour of Fenofibrate in sodium lauryl sulfate solutions. Drug Dev Ind Pharm 31: 917-922.
57. Tanaka Y, Hara T, Waki R, Nagata S,. 2012. Regional differences in the components of luminal water from rat gastrointestinal tract and comparison with other species. J Pharm Pharm Sci 15: 510-518.